@nantpac

New Approaches to Neuroblastoma Therapy (NANT) Parent Advisory Committee

Camp Ronald McDonald for Good Times
Machine Learning Tool Predicts a Child’s Cisplatin-Induced Hearing Loss Risk
Machine Learning Tool Predicts a Child’s Cisplatin-Induced Hearing Loss Risk
Annual Report to the Nation 2025 National Cancer Statistics
Annual Report to the Nation 2025 National Cancer Statistics
Federal cuts to National Institutes of Health could threaten medical progress
Federal cuts to National Institutes of Health could threaten medical progress
Biomarker Testing: Unlocking Personalized Treatments to Improve Patient Outcomes
Biomarker Testing: Unlocking Personalized Treatments to Improve Patient Outcomes
2025 CNCF Parent Conference
ANR 2025 – ADVANCES IN NEUROBLASTOMA RESEARCH MEETING
AACR Legislative Action Center
AACR Legislative Action Center
Welcome! You are invited to join a webinar: International Neuroblastoma Summit: Breaking Boundaries in Research - Session #4: CAR-T with Dr. Francesca Del Bufalo.. After registering, you will receive a confirmation email about joining the webinar.
Welcome! You are invited to join a webinar: International Neuroblastoma Summit: Breaking Boundaries in Research - Session #4: CAR-T with Dr. Francesca Del Bufalo.. After registering, you will receive a confirmation email about joining the webinar.
Driving Standardization of Molecular Testing Guidelines in Pediatric Cancer
Driving Standardization of Molecular Testing Guidelines in Pediatric Cancer
Trahan, Miller-Meeks, Grassley, Bennet Introduce Bipartisan Legislation to Expand Health Care Access For Children
Trahan, Miller-Meeks, Grassley, Bennet Introduce Bipartisan Legislation to Expand Health Care Access For Children
International Neuroblastoma Summit Webinar Registration
International Neuroblastoma Summit Webinar Registration
NANT - Collaborating Labs
NANT - Collaborating Labs
Dr Araz Marachelian, History of NANT & Current Trials
Dr Araz Marachelian, History of NANT & Current Trials
INV724 Earns FDA Rare Pediatric Disease, Orphan Drug Designations for Neuroblastoma
INV724 Earns FDA Rare Pediatric Disease, Orphan Drug Designations for Neuroblastoma
NANT Fall Newsletter 2024.pdf
Long Beach Legacy Triathlon 2024: Mrs. Megan Nelson - Long Beach Triathlon | Children's Hospital Los Angeles
CHLA Neuroblastoma Program
CHLA Neuroblastoma Program
CNCF Parent Conference
Childhood Cancer STAR (Survivorship, Treatment, Access, Research) Act (Public Law No: 115-180)
Sophia's Buddies Supports NANT at Hermosa Beach Tri
Sophia's Buddies Supports NANT at Hermosa Beach Tri
NANT Summer 2024 Newsletter
NANT Summer 2024 Newsletter
Yael P. Mossé, MD | Children's Hospital of Philadelphia
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results - Nature Medicine
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results - Nature Medicine
Blood Product Administration During High Risk Neuroblastoma Therapy
Julie R. Park, MD
Julie R. Park, MD
NANT - Donate
NANT - Donate
Evelyn’s Neuroblastoma Fight
Evelyn’s Neuroblastoma Fight
The EVAN Foundation
The EVAN Foundation
Find Your Representative | house.gov
Cancer Research In Action - Leslie's Thriver Story - V Foundation
Cancer Research In Action - Leslie's Thriver Story - V Foundation
CNCF Parent Conference
A well-meaning FDA policy is a threat to pediatric cancer treatment
A well-meaning FDA policy is a threat to pediatric cancer treatment
NANT - Parent Advisory Committee
NANT - Parent Advisory Committee
NANT Website
NANT - PAC Instagram
NANT - PAC Instagram
NANT - PAC Facebook
NANT - PAC Facebook

View on mobile